In April 2019, Kos designed, developed, and implemented the Flomaxtra® Patient Program through community pharmacies. Flomaxtra® (tamsulosin hydrochloride) tablets 0.4mg is an authority Repatriation Pharmaceutical Benefit and a private Prescription-Only Medicine for other patients. It is used to treat men who have symptoms associated with Benign Prostatic Hyperplasia (also known as BPH).
In March 2018, Kos designed, developed, and implemented the Emerge Health Patient Program. Emerge Health Pty Ltd partnered with PharmaPrograms to facilitate the streamlined dispensing of Sativex® Oromucosal Spray, nabiximols 80 mg/mL pump actuated metered dose aerosol (ARTG ID 181978) through community pharmacies.
In December 2018, Kos designed, developed, and implemented the Osteoporosis Quality Use of Medicines Program with Amgen Australia. This PharmaPrograms initiative is a single intervention targeted at improving adherence rates among patients prescribed any antiresorptive medication.